{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:02:34Z","timestamp":1776690154904,"version":"3.51.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Daiichi Sankyo Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Annually\u2009&gt;\u200910% of patients with atrial fibrillation on oral anticoagulation undergo invasive procedures. Optimal peri-procedural management of anticoagulation, as judged by major bleeding and thromboembolic events, especially in the elderly, is still debated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Procedures from 1442 patients were evaluated. Peri-procedural edoxaban management was guided only by the experience of the attending physician. The primary safety outcome was the rate of major bleeding. Secondary outcomes included the peri-procedural administration of edoxaban, other bleeding events, and the main efficacy outcome, a composite of acute coronary syndrome, non-hemorrhagic stroke, transient ischemic attack, systemic embolic events, deep vein thrombosis, pulmonary embolism, and mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 1442 patients, 280 (19%) were\u2009&lt;\u200965, 550 (38%) were 65\u201374, 514 (36%) 75\u201384, and 98 (7%) were 85\u00a0years old or older. With increasing age, comorbidities and risk scores were higher. Any bleeding complications were uncommon across all ages, ranging from 3.9% in patients\u2009&lt;\u200965\u00a0to 4.1% in those 85\u00a0years or older; major bleeding rates in any age group were\u2009\u2264\u20090.6%. Interruption rates and duration increased with advancing age. Thromboembolic events were more common in the elderly, with all nine events occurring in those\u2009&gt;\u200965, and seven in patients aged\u2009&gt;\u200975\u00a0years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Despite increased bleeding risk factors in the elderly, bleeding rates were small and similar across all age groups. However, there was a trend toward more thromboembolic complications with advancing age. Further efforts to identify the optimal management to reduce ischemic complications are needed.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic>: NCT# 02950168, October 31, 2016<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-020-01766-w","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T02:03:03Z","timestamp":1606788183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Elderly patients with atrial fibrillation in routine clinical practice\u2014peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3601-8187","authenticated-orcid":false,"given":"M.","family":"Unverdorben","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"von Heymann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Santamaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Vanassche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.\u00a0","family":"Laeis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Wilkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Colonna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,1]]},"reference":[{"issue":"9","key":"1766_CR1","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1113\/EP086205","volume":"102","author":"TBL Kirkwood","year":"2017","unstructured":"Kirkwood TBL. Why and how are we living longer? Exp Physiol. 2017;102(9):1067\u201374.","journal-title":"Exp Physiol"},{"issue":"9","key":"1766_CR2","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.117.309732","volume":"120","author":"L Staerk","year":"2017","unstructured":"Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017;120(9):1501\u201317.","journal-title":"Circ Res"},{"issue":"2","key":"1766_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/03602530902722679","volume":"41","author":"U Klotz","year":"2009","unstructured":"Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67\u201376.","journal-title":"Drug Metab Rev"},{"issue":"8","key":"1766_CR4","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/17512433.2019.1632188","volume":"12","author":"G Koren","year":"2019","unstructured":"Koren G, Nordon G, Radinsky K, Shalev V. Clinical pharmacology of old age. Expert Rev Clin Pharmacol. 2019;12(8):749\u201355.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1766_CR5","unstructured":"Lee P, Regenbogen S, Gawande A. How many surgical procedures will Americans experience in an average lifetime? Evidence from three states. In: Poster P15 Massachusetts chapter of the American College of Surgeons. 2008 55th annual meeting. https:\/\/mcacs.org\/abstracts\/2008\/P15.cgi. Accessed 24 Jan 2020."},{"key":"1766_CR6","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 study. Circulation. 2014;129:837\u201347.","journal-title":"Circulation"},{"issue":"22","key":"1766_CR7","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMra1206531","volume":"368","author":"TH Baron","year":"2013","unstructured":"Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med. 2013;368(22):2113\u201324.","journal-title":"N Engl J Med"},{"issue":"11","key":"1766_CR8","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","volume":"179","author":"JD Douketis","year":"2019","unstructured":"Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Int Med. 2019;179(11):1469\u201378.","journal-title":"JAMA Int Med"},{"key":"1766_CR9","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1093\/ageing\/afv071","volume":"44","author":"A Wolff","year":"2015","unstructured":"Wolff A, Shantsila E, Lip GY, Lane DA. Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice. Age Ageing. 2015;44:874\u20138.","journal-title":"Age Ageing"},{"key":"1766_CR10","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1253\/circj.CJ-14-0344","volume":"78","author":"M Akao","year":"2014","unstructured":"Akao M, Chun YH, Esato M, et al. Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J. 2014;78:2166\u201372.","journal-title":"Circ J."},{"issue":"7","key":"1766_CR11","doi-asserted-by":"publisher","first-page":"e005657","DOI":"10.1161\/JAHA.117.005657","volume":"6","author":"G Patti","year":"2017","unstructured":"Patti G, Lucerna M, Pecen L, et al. Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub-analysis from the PREFER in AF (prevention of thromboembolic events-European registry in atrial fibrillation). J Am Heart Assoc. 2017;6(7):e005657.","journal-title":"J Am Heart Assoc"},{"key":"1766_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23379","author":"P Colonna","year":"2020","unstructured":"Colonna P, von Heymann C, Santamaria A, et al. Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF\/VTE study. Clin Cardiol. 2020. https:\/\/doi.org\/10.1002\/clc.23379.","journal-title":"Clin Cardiol"},{"issue":"9","key":"1766_CR13","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/clc.23037","volume":"41","author":"P Colonna","year":"2018","unstructured":"Colonna P, von Heymann C, Santamaria A, et al. Edoxaban management in diagnostic and therapeutic procedures (EMIT-AF\/VTE)-trial design. Clin Cardiol. 2018;41(9):1123\u20139.","journal-title":"Clin Cardiol"},{"issue":"12","key":"1766_CR14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/clc.23279","volume":"42","author":"R De Caterina","year":"2019","unstructured":"De Caterina R, Agnelli G, Laeis P, et al. The global edoxaban treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design. Clin Cardiol. 2019;42(12):1147\u201354.","journal-title":"Clin Cardiol"},{"issue":"1","key":"1766_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","volume":"8","author":"S Schulman","year":"2010","unstructured":"Schulman S, Angeras U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8(1):202\u20134.","journal-title":"J Thromb Haemost"},{"issue":"16","key":"1766_CR16","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330\u201393.","journal-title":"Eur Heart J"},{"issue":"9","key":"1766_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/clc.22435","volume":"38","author":"W Zhu","year":"2015","unstructured":"Zhu W, He W, Guo L, et al. The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol. 2015;38(9):555\u201361.","journal-title":"Clin Cardiol"},{"issue":"31","key":"1766_CR18","doi-asserted-by":"publisher","first-page":"e16560","DOI":"10.1097\/MD.0000000000016560","volume":"98","author":"A Ga\u017eov\u00e1","year":"2019","unstructured":"Ga\u017eov\u00e1 A, Leddy JJ, Rexov\u00e1 M, et al. Predictive value of CHA2DS2-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant). Medicine (Baltimore). 2019;98(31):e16560.","journal-title":"Medicine (Baltimore)"},{"key":"1766_CR19","unstructured":"https:\/\/unstats.un.org\/unsd\/publication\/SeriesM\/SeriesM_74e.pdf. Accessed 22 Jan 2020."},{"key":"1766_CR20","unstructured":"Guidance for Industry E7 Studies in Support of Special Populations: Geriatrics Questions and AnswersE7 FDA Guidance Document on Definition of Elderly current as of 2018 https:\/\/www.fda.gov\/media\/78220\/download. Retrieved on 27 Mar 2020."},{"issue":"4","key":"1766_CR21","first-page":"489","volume":"12","author":"S Singh","year":"2014","unstructured":"Singh S, Bajorek B. Defining \u2018elderly\u2019 in clinical practice guidelines for pharmacotherapy. Pharm Pract. 2014;12(4):489.","journal-title":"Pharm Pract"},{"issue":"1","key":"1766_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.pop.2015.10.001","volume":"43","author":"KB Smith","year":"2016","unstructured":"Smith KB, Smith MS. Obesity statistics. Prim Care. 2016;43(1):121\u201335.","journal-title":"Prim Care"},{"issue":"28","key":"1766_CR23","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1093\/eurheartj\/eht557","volume":"35","author":"J Beyer-Westendorf","year":"2014","unstructured":"Beyer-Westendorf J, Gelbricht V, Forster K, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden DOAC registry. Eur Heart J. 2014;35(28):1888\u201396.","journal-title":"Eur Heart J"},{"issue":"11","key":"1766_CR24","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1253\/circj.CJ-15-0621","volume":"79","author":"E Kodani","year":"2015","unstructured":"Kodani E, Atarashi H, Inoue H, et al. Use of warfarin in elderly patients with non-valvular atrial fibrillation\u2014subanalysis of the J-RHYTHM Registry. Circ J. 2015;79(11):2345\u201352.","journal-title":"Circ J"},{"issue":"3","key":"1766_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.111.090464","volume":"126","author":"JS Healey","year":"2012","unstructured":"Healey JS, Eikelboom J, Douketis J, et al. Peri-procedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation. 2012;126(3):343\u20138.","journal-title":"Circulation"},{"key":"1766_CR26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","volume":"130","author":"JL Halperin","year":"2014","unstructured":"Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130:138\u201346.","journal-title":"Circulation"},{"key":"1766_CR27","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1136\/heartjnl-2016-310358","volume":"103","author":"MN Lauw","year":"2017","unstructured":"Lauw MN, Eikelboom JW, Coppens M, et al. Effects of dabigatran according to age in atrial fibrillation. Heart. 2017;103:1015\u201323.","journal-title":"Heart"},{"issue":"6","key":"1766_CR28","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1212\/01.wnl.0000267275.68538.8d","volume":"69","author":"Stroke Risk in Atrial Fibrillation Working Group","year":"2007","unstructured":"Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69(6):546\u201354.","journal-title":"Neurology"},{"issue":"9","key":"1766_CR29","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1056\/NEJMoa1501035","volume":"373","author":"JD Douketis","year":"2015","unstructured":"Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373(9):823\u201333.","journal-title":"N Engl J Med"},{"key":"1766_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.arr.2018.10.006","volume":"49","author":"ET Kato","year":"2019","unstructured":"Kato ET, Goto S, Giugliano RP. Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. Ageing Res Rev. 2019;49:115\u201324.","journal-title":"Ageing Res Rev"}],"updated-by":[{"DOI":"10.1186\/s12872-021-01873-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000}}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01766-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-020-01766-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01766-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T15:57:19Z","timestamp":1613577439000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-020-01766-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1766"],"URL":"https:\/\/doi.org\/10.1186\/s12872-020-01766-w","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12872-021-01873-2","asserted-by":"object"}]},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"26 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12872-021-01873-2","URL":"https:\/\/doi.org\/10.1186\/s12872-021-01873-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In all countries participating in the study, approval was obtained from a central Ethics Committee and several site-specific Ethics Committees. The study was conducted in accordance with the Declaration of Helsinki and with local Institutional Review Board approvals and was registered as NCT02950168. Please find the complete list of Ethics Committees that provided approval in the Additional file . Written informed consent was obtained from participants prior to enrolment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable: no identifiable subjects are described.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PC reports grants and personal fees from Daiichi Sankyo Europe and personal fees from Daiichi Sankyo Italy during the conduct of the study; personal fees from Boehringer Ingelheim, Bayer\u00a0AG, and Pfizer\/BMS; and non-financial support from the European Society of Cardiology and the Italian Cardiology Association outside the submitted work. CvH reports grants and personal fees from Daiichi Sankyo Europe and Daiichi Sankyo Germany during the conduct of the study; personal fees from Boehringer Ingelheim, Bayer AG, Pfizer GmbH, CSL Behring, NovoNordisk Pharma, Mitsubishi Pharma, Ferring GmbH, Biotest GmbH, and Leo Pharma GmbH outside the submitted work; that he was mandated from the German Society of Anaesthesiology and Intensive Care Medicine to write the German Guideline on Preoperative Anaemia (published in April 2018); was part of the writing group of the Patient Blood Management Guideline in cardiac surgery on behalf of the European Society of Cardiothoracic Anaesthesiologists in conjunction with the European Society of Cardiothoracic Surgery (published in September 2017); and was mandated to take part in the writing group of the guideline on the Diagnostics and Treatment of Peripartum Haemorrhage of the Deutsche Gesellschaft f\u00fcr Gyn\u00e4kologie und Geburtshilfe (published in March 2016). AS reports nothing to disclose. MS reports grants and personal fees from Daiichi Sankyo Europe and personal fees from Daiichi Sankyo UK during the conduct of the study. TV reports grants and personal fees from Daiichi Sankyo Europe; and personal fees from Daiichi Sankyo Be, Bayer, 367 Leo Pharma, and Boehringer Ingelheim during the conduct of the study. PL, CC, and MU are employees of Daiichi Sankyo. RW reports personal fees from Daiichi Sankyo, Inc., during the conduct of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"504"}}